Prostate Knowledge

Investigators unveil metastatic prostate cancer’s genomic landscape

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Localized prostate cancer that is diagnosed before it has a chance to spread typically responds well to surgery or radiation. But when a tumor metastasizes and sends malignant cells elsewhere in the body, the prognosis worsens. Better treatments for men with metastatic prostate cancer are urgently needed. In 2018, scientists advanced toward that goal by […]

A new option for immunotherapy in metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Dividing cells face daunting challenges when replicating the billions of letters of DNA in their genomes. For instance, DNA letters in new cells can get mixed up, and then the affected genes don’t function correctly. To fix that problem, healthy cells can deploy so-called mismatch repair (MMR) genes that put scrambled DNA letters back in […]

Q&A with Dr. Daniel Rukstalis on prostatic urethral lift for enlarged prostates

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

A new procedure that relieves symptoms without causing sexual side effects As men get older, their prostates often get bigger and block the flow of urine out of the bladder. This condition, which is called benign prostatic hyperplasia, causes bothersome symptoms. Since men can’t fully empty their bladders, they experience sudden and frequent urges to […]

New blood test guides researchers toward the best treatment for aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Tumors that spread, or metastasize, in the body shed cells into blood that doctors can scrutinize for insights into what a patient’s cancer might do. Analyzing these so-called circulating tumor cells (CTCs) isn’t part of routine care yet, in part because they’re so hard to pick out of the millions of normal cells in a […]

Influential task force issues new recommendations on prostate cancer screening

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Back in 2012, the US Preventive Services Task Force (USPSTF) took aim at the prostate-specific antigen (PSA) screening test for prostate cancer with a blanket recommendation against it for all men. This was a big deal. The Task Force is widely seen as the top expert panel on cancer screening in the United States, and […]

Diagnostic MRIs allow some men flagged by PSA screening to avoid a biospy, new study shows

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

A specialized type of diagnostic MRI scan can reduce the number of invasive prostate biopsies by nearly a third, according to results from a newly published international study. An MRI machine uses a very large magnet, a radio-wave transmitter, and a computer to construct detailed pictures of structures inside the body. The new study relied […]

New study once again casts doubt on PSA screening

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

To screen or not to screen for prostate cancer? This remains an important question. Screening relies on a highly imperfect measure, the prostate-specific antigen (PSA) blood test, which is prone to false-positive results. And with mounting evidence that survival benefits from screening pale in comparison with the harms from overtreatment — particularly incontinence and impotence […]

A mix of treatments may extend life for men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

For men diagnosed with aggressive cancer that’s confined to the prostate and nearby tissues, the overarching goal of treatment is to keep the disease from spreading (or metastasizing) in the body. Doctors can treat these men with localized therapies, such as surgery and different types of radiation that target the prostate directly. And they can […]

FDA approves new drug for men at high risk of prostate cancer spread

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

A newly approved drug called apalutamide is giving hope to thousands of men confronting a tenacious problem after being treated for prostate cancer. Prostate-specific antigen (PSA) levels should plummet to zero after surgery, and to near zero after radiation therapy, but in some men, they continue rising even when there’s no other evidence of cancer […]

Newer drugs are improving survival for men with metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.